Recent studies have centered on the convergence of glucagon-like peptide-1|GIP|GCGR stimulant therapies and dopaminergic communication. While GLP activators are commonly employed for addressing type 2 diabetes, their unexpected impacts on motivation circuits, specifically governed by DA networks, are receiving considerable attention. This article p